Table 2_KRASG12C inhibitors versus chemotherapy alone for KRASG12C-mutated non-small cell

A pooled meta-analysis of two phase 3 randomized controlled trials involving 798 patients with KRASG12C-mutated non-small cell lung cancer. The dataset, authored by Shuang Liang and last updated in April 2026, compares the efficacy and safety of KRASG12C inhibitors against conventional chemotherapy. It includes results for progression-free survival, central nervous system progression-free survival, objective response rate, disease control rate, and treatment-related adverse events.

Use Cases

• Compare progression-free survival (PFS) and central nervous system-PFS (CNS-PFS) hazard ratios between treatment groups.
• Analyze objective response rate (ORR) and disease control rate (DCR) improvements from KRASG12C inhibitors.
• Evaluate the safety profile of KRASG12C inhibitors based on treatment-related adverse event (TRAE) rates and severity.
• Conduct subgroup analyses to assess the consistency of treatment benefits across different patient populations.

Strengths

• Data is derived from two phase 3 randomized controlled trials, a gold-standard study design.
• Analysis includes 798 patients, providing a substantial sample size for the meta-analysis.
• Results include specific hazard ratios and p-values for primary and secondary endpoints.
• Reports specific incidence rates for top grade 3–5 adverse events like diarrhea (7.63%).

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• The dataset is a 30.0 KB DOC file, suggesting it contains summary results rather than raw patient-level data.
• Geographic and demographic coverage of the included trial populations is not specified.

Provenance

Source

figshare, author Shuang Liang

Collection Method

Systematic literature review and meta-analysis of identified phase 3 RCTs.

Freshness

Last updated 2026-04-15 05:47:44